A murine model of hereditary hemorrhagic telangiectasia

Journal of Clinical Investigation

Volumn 104, Issue 10, 1999, Pages 1343-1351

  Bourdeau, Annie ^a   Dumont, Daniel J ^b   Letarte, Michelle ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOCARDIUM; ENDOTHELIUM CELL; EPISTAXIS; GESTATIONAL AGE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; YOLK SAC;

EID: 0032720393     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8088     Document Type: Article

References (42)

1. Guttmacher, A.E., Marchuk, D.A., and White, R.I.J. 1995. Hereditary hemorrhagic telangieccasia. N. Engl. J. Med. 333:918-924.
2. McAllister, K.A., et al. 1994. Endoglin, a TGF-β binding protein of endothelial cells is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 8:345-351.
3. Heutink, P., et al. 1994. Linkage of hereditary haemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity. J. Med. Genet. 31:933-936.
4. McAllister, K.A., et al. 1994. Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype. J. Med. Genet. 31:927-932.
5. Porteous, M.E.M., et al. 1994. Genetic heterogeneity in hereditary haemorrhagic telangiectasia. J. Med. Genet. 31:925-926.
6. Berg, J.N., Guttmacher, A.E., Marchuk, D.A., and Porteous, M.E.M. 1996. Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin? J. Med. Genet. 33:256-257.
7. Johnson, D.W., et al. 1996. Mutations in the activin receptor-like kinase 1 gene in hereditary hemorrhagic telangiectasia type 2. Nat. Genet. 13:189-195.
8. Pece, N., et al. 1997. Mutant endoglin in hereditary hemorrhagic telangiectasia type I is transiently expressed intracellularly and is nota dominant negative. J. Clin. Invest. 100:2568-2579.
9. Shovlin, C.L., Hughes, J.M.B., Scott, J., Seidman, C.E., and Seidman, J.G. 1997. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am. J. Hum. Genet. 61:68-79.
10. Gougos, A., and Letarte, M. 1988. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J. Immunol. 141:1925-1933.
11. Letarte, M., Greaves, A., and Vera, S. 1995. CD105 (endoglin) cluster report. In Leukocyte typing V: white cell differentiation antigens. S.F. Schlossman et al., editors. Oxford University Press. Oxford, United Kingdom. 1756-1759.
12. St.-Jacques, S., Cymerman, U., Pece, N., and Letarte, M. 1994. Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-β binding protein of endothelial and stromal cells. Endocrinology. 134:2645-2657.
13. Cheifetz, S., et al. 1992. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J. Biol. Chem. 267:19027-19030.
14. Letamendia, A., et al. 1998. Role of endoglin in cellular responses to transforming growth factor-β. A comparative study with betaglycan. J. Biol. Chem. 273:33011-33019.
15. Pece, B.N., Wrana, J., and Letarte, M. 1999. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J. Biol. Chem. 274:584-594.
16. 1. J. Cell Biol. 133:1109-1121.
17. Caniggia, I., Taylor, C.V., Ritchie, J.W.K., Lye, S.J., and Letarte, M. 1997. Endoglin regulates trophoblast differentiation along the invasive pathway in human placental villous explants. Endocrinology. 138:4977-4988.
18. Puri, M.C., Rossant, J., Alitalo, K., Bernstein, A., and Partanen, J. 1995. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 14:5884-91.
19. Risau, W. 1997. Mechanisms of angiogenesis. Nature. 286:671-674.
20. Li, D.Y., et al. 1999. Defective angiogenesis in mice lacking endoglin. Science. 284:1534-1537.
21. Folkman, J., and D'Amore, P.A. 1996. Blood vessel formation: what is its molecular basis? Cell. 87:1153-1155.
22. Dickson, M.C., et al. 1995. Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development. 121:1845-1854.
23. Oshima, M., Oshima, H., and Taketo, M.M. 1996. TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev. Biol. 179:297-302.
24. Lindahl, P., Johansson, B.R., Leveen, P., and Betsholtz, C. 1997. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 277:242-245.
25. Hellström, M., Kalén, M., Lindhal, P., Abramsson, A., and Betsholtz, C. 1999. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 126:3047-3053.
26. Suri, C., et al. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 87:1171-1180.
27. Dumont, D.J., et al. 1994. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 8:1897-1909.
28. Sato, T.N., et al. 1995. Distinct roles of the receptor tyrosine kinases Tie1 and Tie-2 in blood vessel formation. Nature. 376:70-74.
29. Vikkula, M., et al. 1996. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 87:1181-1190.
30. Braverman, I.M., Keh, A., and Jacobson, B.S. 1990. Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J. Invest. Dermatol. 95:422-427.
31. Qu, R., Silver, M.M., and Letarte, M. 1997. Distribution of endoglin in early human development reveals high levels on endocardial cushion tissue mesenchyme during valve formation. Cell Tissue Res. 292:323-343.
32. Letterio, J.J., et al. 1994. Maternal rescue of transforming growth factor-β1 null mice. Science. 264:1936-1938.
33. Akhurst, R.J., Dickson, M., and Millan, F.A. 1994. Transforming growth factor βs and cardiac development. In Growth factors and the cardiovascular system. P. Cummins, editor. Kluwer Academic Publishers. Boston, MA. 347-366.
34. Potts, J.D., Dagle, J.M., Walder, J.A., Weeks, D.L., and Runyan, R.B. 1991. Epithelial-mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligonucleotide to transforming growth factor β3. Proc. Natl. Acad. Sci. USA. 88:1516-1520.
35. Runyan, R.B., Potts J.D., and Weeks, D.L. 1992. TGF-β3-mediated tissue interaction during embryonic heart development. Mol. Reprod. Dev. 32:152-159.
36. Brown, C.B., Boyer, A.S., Runyan, R.B., and Barnett, J.V. 1996. Antibodies to the type II TGF-β receptor block cell activation and migration during atrioventricular cushion transformation in the heart. Dev. Biol. 174:248-257.
37. Vincent, E.B., Runyan, R.B., and Weeks, D.L. 1998. Production of the transforming growth factor-β binding protein endoglin is regulated during chicken heart development. Dev. Dyn. 213:237-247.
38. Brown, C.B., Boyer, A.S., Runyan, R.B., and Barnett, J.V. 1999. Requirement of type II TGF-β receptor for endocardial cell transformation in the heart. Science. 283:207-209.
39. Elsaghier, A.A.F., and McLaren, D.J. 1989. Schistosoma mansoni: evidence that vascular abnormalities correlate with the "non-permissive" trait in 129/Ola mice. Parasitology. 99:377-81.
40. Coulson, P.S., and Wilson, R.A. 1989. Portal shunting and resistance to Schistosoma mansoni in 129 strain mice. Parasitology. 99:383-89.
41. Shovlin, C., and Letarte, M. 1999. Hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: Issues in clinical management and review of pathogenic mechanisms. Thorax. 54:714-729.
42. Smith, B.R. 1999. Visualizing human embryos. Sci. Am. 280:76-81.